Search results
-
KAT6 catalysts to kick off 2025
… with Faslodex, and monotherapy data were last reported at ASCO 2024, showing an 11% ORR . The good news is that …
- 01/08/2025 - 13:52 -
Affimed needs more time with AFM24
… of AFM24 + Tecentriq in relapsed NSCLC ASCO 2024 + Jun 2024 PR Dec 2024 PR …
- 12/18/2024 - 15:56 -
Triple meeting 2024 – Zai Lab impresses in small cell
… Presentation venue Triple meeting 2024 ESMO 2023 ASCO 2024 ORR 74% (14/19)* 40% (40/99) …
- 10/29/2024 - 13:27 -
Sanofi goes deeper into the lead
… SSTR Ph2 AlphaMedix-02 in NETs Data at ASCO 2024: ORR 56% (20/36) in radioligand-therapy naive pts; …
- 10/23/2024 - 14:40 -
AbbVie has Met phase 3, again
… tumours: CRC, GEA, NSCLC Teliso-A +/- Avastin Data at ASCO 2024 in CRC (>35% ORR in high cMet expressers at doses …
- 10/04/2024 - 12:27 -
IMS 2024 – Darzalex fights back against Sarclisa
… Venue International Myeloma Society 2024 ASCO 2024 mPFS NR vs 52.6 months with VRd NR vs … VRd=Velcade, Revlimid & dexamethasone. Source: IMS 2024 & ASCO 2024. Conferences Trial …
- 10/01/2024 - 14:33 -
Akeso builds up its ivonescimab ambitions again
… 2nd-line NSCLC Ivonescimab + chemo Chemo Data ASCO 2024: ORR 51% vs 35%, PFS 7.1 vs 4.8mo; OS 17.1 vs …
- 09/26/2024 - 12:56 -
ESMO 2024 – combos could be the way forward for CDK2
… Presentation ESMO 2024 ESMO 2024 ASCO 2023 ASCO 2024 Study Ph1 in solid tumours …
- 09/15/2024 - 21:18 -
Replimune goes pivotal in uveal melanoma
… R-, GM-CSF & anti-CTLA-4 Ph1 uveal melanoma data at ASCO 2024; ph2/3 begins Jan 2025 Note: …
- 09/06/2024 - 15:47 -
Regeneron gets another bispecific blow
… x CD28 Solid tumours (+ Libtayo) Ph1/2 data at ASCO 2024: 6% (3/51) ORR in MSS CRC; dose-expansion cohorts …
- 08/23/2024 - 12:44
